Since xCT plays a pivotal role in tumor microenvironment interactions, for example, in the induction of peritumoral neuronal cell death and perifocal edema,2,11 there is a quest for understanding the effects of inhibiting compounds for this transporter.15 A deeper understanding of the effects of xCT inhibition on tumor cells might lead to the development of compounds that break through these tumors’ chemo-resistance, and the elucidation of xCT-inhibitor interaction with healthy brain cells might enable us to develop compounds with less adverse, off-target effects. The gene discussed is SLC7A11; the disease is neoplasm.